Responsive Image

 

 

Responsive Image

Oncología médica




Integrantes del grupo

  Josu Aurrekoetxea Oribe
 
 
  Eider Azkona Uribelarrea
 
 
  María Begoña Calvo Martínez
 
 
  Sergio Carrera Revilla
 
 
  Natalia Fuente Fernández
 
 
  Eluska Iruarrizaga Ovejas
 
 
  Gonzalo López de Argumedo Esnarrizaga
 
 
  Juan Manuel Mañe Martínez
 
 
  Inés Marrodan Ciordia
 
 
  Alberto Muñoz Llarena
 
 
  Itziar Rubio Etxebarria
 
 
  Abigail Ruíz de Lobera Martínez
 
 
  Aintzane Sancho Gutierrez
 
 
  Irene Ugalde Martín
 
 
  Guillermo Humberto Portilla Quattrociocchi
 
 
  Gaizka Mallabiabarrena Ormaetxea
 
 

Publicaciones del grupo:

Arietaleanizbeaskoa MS,Sancho A,Olazabal I,Moreno C,Gil E,Garcia A,Mendizabal N,de la Fuente I,Domínguez S,Pablo S,Grandes G,EfiKroniK G. Effectiveness of physical exercise for people with chronic diseases: the EFIKRONIK study protocol for a hybrid, clinical and implementation randomized trial. BMC Fam. Pract. 2020. 21. (1):p. 227-227. IF:2,022. (2).
Sánchez M,Sánchez A,Bertran S,Abad J,Duran J,Cabriada V,Mediano O,Masdeu MJ,Alonso ML,Masa JF,Barceló A,de la Peña M,Mayos M,Coloma R,Montserrat JM,Chiner E,Perelló S,Rubinós G,Mínguez O,Pascual L,Cortijo A,Martínez D,Aldomà A,Dalmases M,McEvoy RD,Barbé F,Spanish N,Abad L,Muñoz A,Zamora E,Vicente I,Inglés S,Egea C,Marcos J,Fernández A,Ullate J,Durán J,Rodríguez JL,Mendoza MJ,Labeaga R,Diez D,Muria B,Amibilia C,Urrutia A,Castro S,Serrano L,Salinas I,Diez R,Martínez A,Florés M,Galera E,Mas A,Martínez M,Arbonés M,Ortega S,Martín A,Román JM,Valiente MI,Viejo ME,Rodríguez C,Sánchez N,Mayoral N,Rubio FJ,Anta Y,Romera S,Resano P,Arroyo R,Bienvenido M,Vigil L,Ramírez E,Piñar M,Martínez E,Múñoz C,Ordax E,Surname N,Corral J,Gómez de Terreros Caro FJ,García E,Gallego R,Cabrero JL,Pereira R,Giménez P,Carrera M,Pierola J,Villena C,Campaner M,Fortuna AM,Peñacoba P,Martínez AJ,García S,Navas L,Garmendia O,Suárez M,Sancho J,Farre N,Bonet G,Bardaji A,Villares A,Vázquez MJ. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. Lancet Respir Med. 2020. 8. (4):p. 359-367. IF:30,700. (1).
Bjorck M,Earnshaw JJ,Acosta S,Goncalves FB,Cochennec F,Debus ES,Hinchliffe R,Jongkind V,Koelemay MJW,Menyhei G,Svetlikov AV,Tshomba Y,Van Den Berg JC,de Borst GJ,Chakfe N,Kakkos SK,Koncar I,Lindholt JS,Tulamo R,de Ceniga MV,Vermassen F,Boyle JR,Mani K,Azuma N,Choke ETC,Cohnert TU,Fitridge RA,Forbes TL,Hamady MS,Munoz A,Mueller S,Rai K,ESVS C,Document R. Editor's Choice - European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur. J. Vasc. Endovasc. Surg. 2020. 59. (2):p. 173-218. IF:7,069. (1).
Provencio M,Nadal E,Insa A,Garcia MR,Casal J,Domine M,Majem M,Rodriguez D,Martinez A,De Castro J,Cobo M,Lopez G,Del Barco E,Bernabe R,Vinolas N,Barneto I,Viteri S,Pereira E,Royuela A,Casarrubios M,Salas C,Parra ER,Wistuba I,Calvo V,Laza R,Romero A,Massuti B,Cruz A. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020. 21. (11):p. 1413-1422. IF:41,316. (1).
Conte MS,Bradbury AW,Kolh P,White JV,Dick F,Fitridge R,Mills JL,Ricco JB,Suresh KR,Murad MH,Aboyans V,Aksoy M,Alexandrescu VA,Armstrong D,Azuma N,Belch J,Bergoeing M,Bjorck M,Chakfe N,Cheng S,Dawson J,Debus ES,Dueck A,Duval S,Eckstein HH,Ferraresi R,Gambhir R,Gargiulo M,Geraghty P,Goode S,Gray B,Guo W,Gupta PC,Hinchliffe R,Jetty P,Komori K,Lavery L,Liang W,Lookstein R,Menard M,Misra S,Miyata T,Moneta G,Prado J,Munoz A,Paolini JE,Patel M,Pomposelli F,Powell R,Robless P,Rogers L,Schanzer A,Schneider P,Taylor S,de Ceniga MV,Veller M,Vermassen F,Wang JS,Wang SM,Writing Joint Guidelines GVGGRP,E,WFVS. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischaemia (vol 58, pg 1, 2019). Eur. J. Vasc. Endovasc. Surg. 2020. 60(1):p. 158-159. IF:7,069. (1).

Mendizabal Gallastegui, Nere, Arietaleanizbeascoa Sarabia, Marisol, Latorre Garcia, Pedro Maria, Iruarrizaga Ovejas, Eluska, Sancho Gutierrez, Aintzane, Grandes Odriozola, Gonzalo. Physical exercise to improve the quality of life of people in treatment for tumor processes: EFICANCER study. Int. J. Integr. Care. 2019; 19(1). FI: 2,489(Q2). DOI: 10.5334/ijic.s3472.

Karachaliou, Niki, Paulina Bracht, Jillian Wilhelmina, Fernandez Bruno, Manuel, Drozdowskyj, Ana, Capitan, Ana Gimenez, Moran, Teresa, Carcereny, Enric, Cobo, Manuel, Domine, Manuel, Chaib, Imane, Luis Ramirez, Jose, Camps, Carlos, Provencio, Mariano, Vergnenegre, Alain, Lopez-Vivanco, Guillermo, Majem, Margarita, Massuti, Bartomeu, Rosell, Rafael. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer. J. Thorac. Oncol.. 2019; 14(2): 304 - 310. FI: 12,460(Q1). DOI: 10.1016/j.jtho.2018.10.168.

Laza Briviesca, Raquel, Cruz Bermudez, Alberto, Barquin, Miguel, Nadal, Ernest, Insa, Amelia, Garcia-Campelo, Rosario, De Dios Alvarez, Noemi, Domine, Manuel, Massuti, Bartomeu, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez Marti, Alex, Cobo, Manuel, Lopez-Vivanco, Guillermo, del Barco, Elvira, Bernabe, Reyes, Vinolas, Nuria, Barneto, Isidoro, Viteri, Santiago, Provencio-Pulla, Mariano. Haematological biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA non-small cell lung cancer (NSCLC) patients.. J. Clin. Oncol.. 2019; 37. FI: 28,245(Q1). DOI: .

Provencio, Mariano, Nadal, Ernest, Insa, Amelia, Garcia-Campelo, Rosario, Casal Rubio, Joaquin, Domine, Manuel, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez Marti, Alex, Cobo, Manuel, Lopez-Vivanco, Guillermo, del Barco, Elvira, Bernabe, Reyes, Vinolas, Nuria, Barneto, Isidoro, Viteri, Santiago, Martin-Martorell, Paloma, Jove, Maria, Franco, Fabio, Massuti, Bartomeu. Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study-Final data of patients who underwent surgical assessment.. J. Clin. Oncol.. 2019; 37. FI: 28,245(Q1). DOI: .

Urrutia, Ines, Martinez, Rosa, Rica, Itxaso, Martinez de LaPiscina, Idoia, Garcia-Castano, Alejandro, Aguayo, Anibal, Calvo, Begona , Castano, Luis, Fernandez-Ramos, Concepcion, Nunez, Javier, Oriol Casanovas-Marsal, J., Grau, Gema, Rodriguez-Estevez, Amaia, Vela, Amaia, Velasco-Vielba, Olaia, Ferrer, Marta, Lou, Gracia M., Barrio, Raquel, Garcia-Cuartero, Beatriz, Martin-Frias, Maria, Gonzalez, Amparo, Caimari, Maria, de Sotto, Diego, Campos, Ariadna, Clemente, Maria, Gomez-Gila, Ana L., Spanish Pediat Diabet Collaborativ. Negative autoimmunity in a Spanish pediatric cohort suspected of type 1 diabetes, could it be monogenic diabetes?. PLoS One. 2019; 14(7): e0220634. FI: 2,776(Q2). DOI: 10.1371/journal.pone.0220634.

Carrera, Sergio , Beristain, Elena, Sancho, Aintzane , Iruarrizaga, Eluska, Rivero, Pilar, Manuel Mane, Juan, Lopez Vivanco, Guillermo. Germline c.1A > C heterozygous pathogenic variant in SDHA reported for the first time in a young adult with a gastric gastrointestinal stromal tumour (GIST): a case report. Hered. Cancer Clin. Pract.. 2019; 17(1): 23 - 23. FI: 1,780(Q4). DOI: 10.1186/s13053-019-0124-6.

Laza-Briviesca, R., Cruz-Bermudez, A., Casarrubios, M., Nadal, E., Insa Molla, M. A., Garcia-Campelo, M-R., Huidobro, G., Domine Gomez, M., Majem Tarruella, M., Rodriguez Abreu, D., Martinez-Marti, A., De Castro Carpeno, J., Cobo Dols, M., Lopez Vivanco, G., del Barco Morillo, E., Bernabe, R., Vinolas, N., Barneto Aranda, I. C., Massuti Sureda, B., Provencio, M.. Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients. Ann. Oncol.. 2019; 30(5). FI: 14,196(Q1). DOI: .

Massuti Sureda, B., Sanchez Torres, J. M., Cobo Dols, M., Moran Bueno, M. T., Gonzalez-Larriba, J. L., Barneto Aranda, I. C., De Castro Carpeno, J., Iglesias, L., Munoz, M. A., Lopez Vivanco, G., Casado, M. D. Isla, Lopez, R., de las Penas Bataller, R., Rodriguez Abreu, D., Artal-Cortes, A., Esteban, E., Provencio, M., Pereira, E., Sanchez-Paya, J., Rosell, R.. BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial. Ann. Oncol.. 2019; 30(5). FI: 14,196(Q1). DOI: .

Azkona, E., Carrera, S. , Rubio, I., Mane, J. M., Lacambra, I., Sancho, A., Novo, E., Lopez-Vivanco, G.. Influence of Radiotherapy in Second-Line Treatment with Immunotherapy in Patients with Non-Small Cell Lung Cancer. J. Thorac. Oncol.. 2019; 14: 969 - 969. FI: 12,460(Q1). DOI: 10.1016/j.jtho.2019.08.2123.

Laza-Briviesca, R., Cruz-Bermudez, A., Casarrubios, M., Nadal, E., Insa, A., Garcia Campelo, R., De Dios Alvarez, N., Domine, M., Majem, M., Rodriguez-Abreu, D., Calvo De Juan, V., Martinez-Marti, A., De Castro Carpeno, J., Cobo, M., Lopez-Vivanco, G., Del Barco, E., Bernabe, R., Vinolas, N., Barneto, I., Viteri, S., Massuti, B., Provencio, M.. Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients. J. Thorac. Oncol.. 2019; 14: 711 - 711. FI: 12,460(Q1). DOI: 10.1016/j.jtho.2019.08.1515.

Massuti, B., Sanchez, J. M., Cobo, M., Moran, T., Gonzalez Larriba, J. L., Barneto, I., De Castro Carpeno, J., Iglesias, L., Munoz, M. A., Lopez-Vivanco, G., Isla, D., Lopez, R., De Las Penas, R., Rodriguez-Abreu, D., Artal, A., Esteban, E., Provencio, M., Pereira, E., Sanchez-Paya, J., Rosell, R.. Reccurrence Pattern After Adjuvant Customized Chemotherapy Based on BRCA Expression Level (SCAT Trial). J. Thorac. Oncol.. 2019; 14: 252 - 252. FI: 12,460(Q1). DOI: 10.1016/j.jtho.2019.08.502.

Provencio, M., Nadal, E., Insa, A., Garcia Campelo, R., Casal, J., Domine, M., Majem, M., Rodriguez-Abreu, D., Martinez-Marti, A., De Castro Carpeno, J., Cobo, M., Lopez-Vivanco, G., Del Barco, E., Bernabe, R., Vinolas, N., Barneto, I., Viteri, S., Martin Martorell, P., Jove, M., Calvo De Juan, V., Massuti, B.. NADIM Study: Updated Clinical Research and Outcomes. J. Thorac. Oncol.. 2019; 14: 241 - 241. FI: 12,460(Q1). DOI: 10.1016/j.jtho.2019.08.480.

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.. J. Thorac. Oncol.. 2019; 14(12): 2120 - 2132. FI: 12,460(Q1). DOI: 10.1016/j.jtho.2019.07.005.

Arriola E, Paredes-Lario A, García-Gomez R, Diz-Tain P, Constenla M, García-Girón C, et al. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS. Clin. Transl. Oncol. 2018; 20(10): 1261 - 1267. FI: 2,392(Q3). DOI: 10.1007/s12094-018-1855-y.

Conde E, Hernandez S, Martinez R, De Castro J, Collazo-Lorduy A, Jimenez B, et al. Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients. J. Thorac. Oncol. 2018; 13(10): 553 - 554. MEETING ABSTRACT.

Callejo-Goena A, Rubio-Etxebarria I, Sancho-Gutiérrez A, Azkuna-Sagarduy J, Lopetegi-Aizpurua A, López-Vivanco G. Infective endocarditis in a patient with metastatic colorectal cancer. Rev. Esp. Quim. 2018; 31(1): 75 - 77. FI: 0,605(Q4). LETTER.

Redondo A, Vazquez MR, Manso L, Gil MJG, Llinas IG, Garcia-Garre E, et al. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study. OncoTargets Ther.. 2018; 11: 5845 - 5852. FI: 2,656(Q2). DOI: 10.2147/OTT.S170303.

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018; 378(22): 2078 - 2092. FI: 79,258(Q1). DOI: 10.1056/NEJMoa1801005.

Provencio M, Nadal E, Insa A, Campelo RG, Huidobro GG, Domine M, et al. Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer-Nadim Study-SLCG. J. Thorac. Oncol. 2018; 13(10): 320 - 320. MEETING ABSTRACT.

Garcia-Foncillas J, Tabernero J, Elez E, Aranda E, Benavides M, Camps C, et al. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br. J. Cancer. 2018; 119(12): 1464 - 1470. FI: 5,922(Q1). DOI: 10.1038/s41416-018-0293-5.

Carrera S, Sancho A, Azkona E, Azkuna J, Lopez-Vivanco G. Hereditary pancreatic cancer: related syndromes and clinical perspective. Hered Cancer Clin Pract. 2017;15:9. FI:1,590(Q4). DOI:10.1186/s13053-017-0069-6.

Chaib I, Karachaliou N, Pilotto S, Servat JC, Cai XT, Li XF, et al. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in; EGFR-Mutant NSCLC. JNCI-Natl Cancer Inst. 2017;109:djx014 . FI:12,589(Q1). DOI:10.1093/jnci/djx014.

De Juan VC, Molla AI, Dols MC, Sureda BM, Lopez-Vivanco G, Rubio JC, et al. Neo-adjuvant chemo/immunotherapy for the treatment of resectable stage; IIIA non-small cell lung cancer (NSCLC): A phase II multicenter; exploratory study NADIM trial. Ann Oncol. 2017;28:1286TiP. FI:11,855(Q1). ABSTRACT

Foncillas JG, Tabernero J, Aguilar EA, Benavides M, Camps CJ, Lopez R, et al. First prospective multicenter real-world RAS mutation comparison between; OncoBEAM-based liquid biopsy and tissue analysis. Ann Oncol. 2017;28:129P. FI:11,855(Q1). ABSTRACT

Gonzalez MJE, de la Pena FA, Vazquez RM, Garcia-Saenz JA, Calvo EG, Manas JJI, et al. Retrospective observational study to evaluate the use of halaven plus; trastuzumab for the treatment of HER2 metastatic breast cancer (MBC) in Spain: HALATRUST study. Ann Oncol. 2017;28:307P. FI:11,855(Q1). ABSTRACT

Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, Aldeguer E, Cao MG, Cardona AF, et al. Expression of genes associated with anti-viral response in EGFR mutant; non-small cell lung cancer (NSCLC). Ann Oncol. 2017;28:8P. FI:11,855(Q1). ABSTRACT

Karachaliou N, Chaib I, Cardona A, Lopez-Vivanco G, Vergnenegre A, Sanchez JM, et al. Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer. J Thorac Oncol. 2017;12:1216-17. FI:6,595(Q1). DOI:10.1016/j.jtho.2016.11.1714. ABSTRACT

Karachaliou N, Morales-Espinosa D, Vila MAM, Garde J, Baron F, Cobo M, et al. AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study. J Thorac Oncol. 2017;12:1074-5. FI:6,595(Q1). DOI:10.1016/j.jtho.2016.11.1503. ABSTRACT

Lopez-Vivanco G, Salvador J, Diez R, Lopez D, De Salas-Cansado M, Navarro B, De la Haba-Rodriguez J. Cost minimization analysis of treatment with intravenous or subcutaneous; trastuzumab in patients with HER2-positive breast cancer in Spain. Clin Transl Oncol. 2017;19:1454-61. FI:2,353(Q3). DOI:10.1007/s12094-017-1684-4.

Mane JM, Calvo B, Aresti U, Carrera S, Sancho A, Azkona E, et al. Epithelial ovarian cancer and primary peritoneal carcinomatosis in the elderly: what is our clinical practice?. Eur J Gynaecol Oncol. 2017;38:695-9. FI:0,692(Q4). DOI:10.12892/ejgo3674.2017.

Vazquez MR, Redondo A, Manso L, Gil M, Garau I, Perez-Carrion R, et al. Long-term responders to first-line bevacizumab-based therapy in metastatic breast cancer (MBC) patients: Results of the observational study LORENA. J Clin Oncol. 2017;35:e12563. FI:24,008(Q1). DOI:10.1200/JCO.2017.35.15_suppl.e12563. ABSTRACT

Arriola E, Paredes A, Gomez RG, Diz P, Constenla M, Girón CG, et al. 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study. J Thorac Oncol. 2016;11:S122. FI:6,595(Q1). DOI:10.1016/S1556-0864(16)30257-X.

Cacicedo J, Fernandez I, Del Hoyo O, Gomez-Iturriaga A, Martinez-Indart L, Frias A, et al. Prognostic Value of Maximum Standardized Uptake Value Measured by Pretreatment 18F-FDG PET/CT in Locally Advanced Head and Neck Squamous Cell Carcinoma: Adding Value to Clinical Staging. Int J Radiat Oncol Biol Phys. 2016;96:E383. FI:5,133(Q1). ABSTRACT

Camps C, Albanell J, Antón A, Aranda E, Carrato A, Cassinello J, et al. Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique. J Natl Compr Canc Netw. 2016;14:553-8. FI:4,675(Q2).

Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, et al. Treatment patterns of adjuvant interferon-a2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study. Melanoma Res. 2016;26:278-83. FI:2,615(Q2). DOI:10.1097/CMR.0000000000000254.

González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, et al. Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. Curr Cancer Drug Targets. 2016;16:415-28. FI:2,992(Q3). DOI:10.2174/1568009615666150817121731.

Karachaliou N, Chaib I, Cai X, Li X, Cardona AF, Lopez-Vivanco G, et al. Poly-therapy with EGFR, STAT3 and Src-YAP1 signaling pathway inhibition; A breakthrough for EGFR mutant NSCLC. Ann Oncol. 2016;27:1188P. FI:11,855(Q1). DOI:10.1093/annonc/mdw382.2. ABSTRACT

Arrospide A, Soto-Gordoa M, Acaiturri T, Lopez-Vivanco G, Abecia LC, Mar J. Cost of Breast Cancer Treatment by Clinical Stage in the Basque Country, Spain. Rev Esp Salud Publica. 2015;89:93-97. FI:0,600(Q4).

Ayala F, Feijoo M, Martinez N, Gerico, JF, Gomez A, Sanchez P, et al. Clinical profile and prognosis of metastatic breast cancer (MBC) patients with long-lasting response to eribulin (E): Results of the EXTER study. J Clin Oncol. 2015;33:e12022 FI:20,982(Q1). ABSTRACT

Cacicedo J, Fernandez I, del Hoyo O, Dolado A, Gomez-Suarez J, Hortelano E, et al. Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis. Eur J Nucl Med Mol I. 2015;42:1378-1389. FI:5,537(Q1). DOI:10.1007/s00259-015-3071-0.

Capdevila J, Sevilla I, Alonso V, Aparicio LA, Jimenez P, Grande E, et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015;15:495. FI:3,265(Q2). DOI:10.1186/s12885-015-1512-6.

Diaz-Rubio E, Anton A, Aranda E, Carrato A, Gascon P, Lopez-Vivancos G, et al. Developing standards and indicators for quality improvement for cancer patients in Spain. Eur J Cancer. 2015;51:156. FI:6,163(Q1). ABSTRACT

Doval D, Cinieri S, Bozcuk H, Pierga JY, Altundag K, Wang X, et al. Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) +/- capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can. Cancer Res. 2015;75:P2-12-16. FI:8,556(Q1). ABSTRACT

Garcia R, Moran T, Cardenal F, Alonso-Jaudenes G, Carcereny E, Pallares C, et al. BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p). J Clin Oncol. 2015;FI:20,982(Q1). ABSTRACT

Gonzalez-Pinto A, Martinez M, Garcia-Alocen A, Bermudez C, Lopez P. First bipolar episodes and functionality. Relation with depressive symptoms and inflammation. Bipolar Disord. 2015;17:125. FI:4,882(Q1). ABSTRACT

Karachaliou N, Codony-Servat J, Teixido C, Pilotto S, Drozdowskyj A, Codony-Servat C, et al. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep-Uk. 2015;5:17499 FI:5,228(Q1). DOI:10.1038/srep17499.

Lopez G, Carrera S, Rubio I, Azcona E, Sancho A, Calvo B, et al. Final results of a phase II study of bevacizumab, cisplatin and pemetrexed as first-line therapy for patients with advanced non squamous non small cell lung cancer.. J Clin Oncol. 2015;33:e19036.FI:20,982(Q1). ABSTRACT

Massuti B, Cobo M, Rodriguez-Paniagua JM, Ballesteros AI, Moran T, Arrabal R, et al. Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov:00478699). J Clin Oncol. 2015;33:7507.FI:20,982(Q1). ABSTRACT

Massuti B, Rodriguez-Paniagua JM, Cobo M, Arrabal R, Ballesteros I, Pun YW, et al. Results Ph III Trial Customized Adjuvant CT after Resection of NSCLC with Lymph Node Metastases SCAT: A Spanish Lung Cancer Group Trial. J THORAC ONCOL. 2015; 10: 180. FI: 5,040(Q1). ABSTRACT

Sancho A, Carrera S, Arietaleanizbeascoa M, Arce V, Mendizabal N, March AG, et al. Supervised physical exercise to improve the quality of life of cancer patients: the EFICANCER randomised controlled trial. BMC Cancer. 2015;15:40. FI:3,265(Q2). DOI:10.1186/s12885-015-1055-x.

Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, et al; Spanish Lung Cancer Group; French Lung Cancer Group; Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing.Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies(aEuro). Ann Oncol. 2014;25:2147-55. FI: 7,040(Q1)

Aresti U, Carrera S, Iruarrizaga E, Fuente N, Marrodan I, de Lobera AR, et al. Estrogen Receptor 1 Gene Expression and Its Combination with Estrogen Receptor 2 or Aromatase Expression Predicts Survival in Non-Small Cell Lung Cancer. PLoS One. 2014;9:e109659. FI: 3,234(Q1)

Uribarri M, Hormaeche I, Zalacain R, Lopez-Vivanco G, Martinez A, Nagore D, et al. A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis. J Thorac Oncol. 2014;9:1504-12. FI: 5,282(Q1)

Martínez-García MA, Campos-Rodriguez F, Durán-Cantolla J, de la Peña M, Masdeu MJ, González M, et al; Spanish Sleep Network. Obstructive sleep apnea is associated with cancer mortality in younger patients. Sleep Med. 2014;15:742-8. FI: 3,154(Q2)

Carrera S, Buque A, Azkona E, Aresti U, Calvo B, Sancho A, et al. Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. Clin Transl Oncol. 2014;16:339-50. FI: 2,077(Q3)

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al; START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:59-68. FI: 24,690(Q1)

Martin-Algarra S, Soriano V, Malvehy J, Berrocal A, Quindos M, Martinez Del Prado P, et al. Treatment patterns of adjunvant interferon ALFA-2B(IFN-alpha 2B) for high-risk melanoma. A retrospective study of the grupo espanol multidisciplinary de melanoma. (GEM). Ann Oncol. 2014;25(suppl 4):1123. FI: 7,040(Q1)

Cacicedo J, Del Hoyo O, Rodeno E, Fernandez I, Rodriguez O, Dolado A, et al. Utility Of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET/CT) in the Staging and Treatment Plan Evaluation of Head and Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2014;90:552. FI: 4,258(Q1)

Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, Isla D, Galán A, Bover I, Domine M, Vicente V, Rosell R, Rocha E. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Resultsfromthe ABEL study. Thromb Res. 2013;132:666-70. FI: 3,133(Q2)

Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHerStudyGroup. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962-70. FI: 25,117(Q1)

Castellano D, Garcia del Muro X, Climent MA, Maroto P, Perez-Gracia JL, Lopez-Vivanco G, Zhang K, Fly K, Hariharan S, Anton-Aparicio L. Sunitinib expanded-access trial in metastatic renal cell carcinoma (mRCC) - final results from Spain. Eur  J Cancer.  2013; 49: 666.FI: 5,061(Q1)

Buqué A, Aresti U, Calvo B, ShMuhialdin J, Muñoz A, Carrera S, Azkona E, Rubio I, López-Vivanco G. Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells. PLoS One. 2013;8:e63338. FI: 3,730(Q1)

De Cock E, Semiglazov V, Lopez Vivanco G, Verma S, Pivot X, Gligorov J, Hauser N, Urspruch A, Kritikou P, Knoop A. Time savings with trastuzumab subcutaneous vs intravenous administration: a time and motion study. Breast 2013;22: S88.  FI: 1,967(Q2).

E Alba, E Ciruelos, R López, JM López-Vega, A Lluch, M Martín, et al.  Cost–Utility Analysis of NanopA Albumin-Bound Paclitaxel versus Paclitaxel in Monotherapy in Pretreated Metastatic Breast Cancer in Spain. Expert Rev Pharmacoeconomics Outcomes Res 2013;13:381-91.

Tesis del grupo:

Autor/a: Eider Azkona Uribelarrea. Título: Respuesta clínica en pacientes con cáncer colorrectal metastásico y farmacodinamia del irinotecán en los mismos. Directores: Dr. Guillermo López Vivanco, Dra. Begoña Calvo Martínez.

Buqué Martínez A, López Vivanco G (dirección). Effect of multitargeted antifolate on human metastatic melanoma cell lines. Molecular pathways and resistance mechanisms.

© 2021 IIS Biocruces Bizkaia